

# BeiGene Pipeline Portfolio

Three late-stage, and 12 early-stage clinical assets (not including compounds from Amgen collaboration)



As of 4/23/2020

	ASSETS	PROGRAMS	DOSE ESC.	DOSE EXPANSION		PIVOTAL		FILED	MARKET	COMMERCIAL RIGHTS	PARTNER	
			PH1a	PH1b	PH2*	PH2**	PH3					
Internally Developed	zanubrutinib (BTK)	monotherapy	R/R MCL (Accelerated approval in the U.S. Nov. 14, 2019)							Global		
			R/R MCL, R/R CLL/SLL (NDAs accepted by NMPA)									
			R/R WM									
			WM, 1L CLL/SLL, R/R CLL/SLL									
			R/R MZL									
			Previously treated CLL/SLL (ibrutinib intolerant)									
	tislelizumab (PD-1)	monotherapy	R/R cHL (approved December 26, 2019)							Global		
			2L+ UC (approved April 10, 2020)									
			2L NSCLC, 1L HCC, 2L ESCC									
			2L/3L HCC									
			R/R NK/T-cell lymphoma									
			1L Sq. NSCLC (sNDA accepted April 4, 2020)									
	pamiparib (PARP)	monotherapy	1L Non-Sq. NSCLC, 1L NPC, 1L SCLC							Global		
			1L GC, 1L ESCC									
			+ chemo	Solid tumors								
				B-cell malignancies								
			+ pamiparib (PARP)	1L platinum-sensitive GC maintenance								
				2L platinum-sensitive OC maintenance								
	+ RT/TMZ (RT/chemo)	3L gBRCA+ OC										
		Solid tumors										
Collaborations	lifirafenib (RAF Dimer)	monotherapy	Solid tumors							Global		
			B-Raf- or K-RAS/N-RAS-mutated solid tumors									
	BGB-A333 (PD-L1)	monotherapy & + tislelizumab	Solid tumors							Global		
	BGB-A425 (TIM-3)	monotherapy & + tislelizumab	Solid tumors							Global		
	BGB-A1217 (TIGIT)	+ tislelizumab	Solid tumors							Global		
	BGB-A445 (OX40)	+ tislelizumab	Solid tumors							Global		
	BGB-11417 (Bcl-2)	monotherapy & + zanubrutinib	Phase 1 study startup ongoing							Global		
	Sitravatinib	(multi-kinase inhibitor)	NSCLC, RCC, OC, MEL, HCC/GEJ							Asia ex-Japan, AU, NZ	Mirati	
	ZW25	(bispecific HER2 antibody)	Breast, Gastric & Gastroesophageal Junction Cancer							Asia ex-Japan, AU, NZ	Zymeworks	
	ZW49	(bispecific anti-HER2 ADC)	Planned (in Ph1 ex-China by Zymeworks)							Asia ex-Japan, AU, NZ	Zymeworks	
BGB-3245	(B-RAF)	Solid tumors							Asia ex-Japan	SpringWorks <sup>1</sup>		
SEA-CD70	(anti-CD70)	Planned (starting Ph.1 ex-Asia by Seattle Genetics)							Asia ex-Japan, AU, NZ	Seattle Genetics		
DKN-01	+ tislelizumab	Trials in GC/GEJ planned							Asia ex-Japan, AU, NZ	Leap Therapeutics		

\*Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. \*\*Confirmatory clinical trials post approval are required for accelerated approvals. 1.By MapKure, a JV with SpringWorks